<DOC>
	<DOCNO>NCT00205608</DOCNO>
	<brief_summary>Patients schizophrenia volume loss gray matter . This study design evaluate whether microglia activation schizophrenia use [ 11C ] ( R ) -PK11195 PET .</brief_summary>
	<brief_title>Microglia Activation Schizophrenia</brief_title>
	<detailed_description>Schizophrenia complex chronic disease affect different aspect cognition behaviour , include attention , perception , think process , emotion volition . Schizophrenia brain disease particularly involve decrement gray matter support finding many image study . The pathophysiology gray matter change clarify . Microglia activation consequence virtually condition associate neuronal injury . When activate follow neuronal damage , microglia show mark increase expression peripheral type benzodiazepine bind site particularly abundant cell mononuclear macrophage . ( R ) -PK11195 [ 1- ( 2-chlorophenyl ) -N-methyl-N-1 ( 1-methylpropyl ] -3 isoquinolinecarboxamide ) highly selective ligand peripheral benzodiazepine bind site . ( R ) -PK11195 , label positron emitter carbon-11 , use monitor peripheral type benzodiazepine receptor use Positron Emission Tomography ( PET ) . At Vrije Universiteit Medical Centre ( R ) - [ 11C ] PK11195 use study microglia activation in-vivo patient traumatic brain damage , minimal cognitive impairment Alzheimer disease . The objective study determine whether extent microglia activation occur schizophrenia . Ten patient schizophrenia recruit 10 control , match age gender . This open study . The study consist one PET scan , perform Clinical PET Centre Vrije Universiteit Medical Centre . All subject also get MRI scan , perform department Radiology , University Medical Centre Utrecht .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Schizophrenia accord DSMIV criterion confirm diagnostic interview ( CASH , patient ) within first 5 year initial diagnosis Male Females Good physical mental ( control ) Health evaluate medical history , physical examination screen laboratory test ( see appendix 1 ) . Age 18 40 year ( 10 patient 10 control ) Mini Mental State score &gt; 27 . Written inform consent subject . Hb must &gt; 8 mmol \ litre time screen . Previous neurotrauma loss consciousness Any clinical significant abnormality clinical laboratory test , include drug screening . Any subject receive investigational medication within 30 day prior start study , schedule receive investigational drug . major current psychiatric diagnosis axis1 DSMIV ( patient ) History psychiatric neurological illness ( control ) History psychiatric neurological illness firstdegree relative ( control ) History alcohol and/or drug abuse ( DSMIV criterion ) Blood donation within 3 month scan day Claustrophobia Metal object around body ( brace , pacemaker , metal fragment ) ; Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>microglia</keyword>
	<keyword>PET</keyword>
</DOC>